Cart
sales@molnova.com
GSK-3 Inhibitor XIII
CAS No. 404828-14-4
GSK-3 Inhibitor XIII( —— )
Catalog No. M37201 CAS No. 404828-14-4
GSK-3 Inhibitor XIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 252 | In Stock |
|
| 5MG | 242 | In Stock |
|
| 10MG | 436 | In Stock |
|
| 25MG | 934 | In Stock |
|
| 50MG | 1256 | In Stock |
|
| 100MG | 1693 | In Stock |
|
| 200MG | 2288 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-3 Inhibitor XIII
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-3 Inhibitor XIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.
-
DescriptionGSK-3 Inhibitor XIII is a potent and ATP-competitive GSK-3 inhibitor with a Ki of 24 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number404828-14-4
-
Formula Weight301.35
-
Molecular FormulaC18H15N5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (331.84 mM; Ultrasonic )
-
SMILESN=1NC(=CC1NC=2N=C(N=C3C=CC=CC32)C=4C=CC=CC4)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Albert C Pierce, et al. CH...O and CH...N hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor. J Med Chem. 2005 Feb 24;48(4):1278-81. ?
molnova catalog
related products
-
VP3.15 dihydrobromid...
VP3.15 dihydrobromide is a potent orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE7- glycogen synthase kinase (GSK)3 inhibitor(with IC50s of 1.59 μM 0.88 μMrespectively.)
-
AZD2858
AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, inhibits tau phosphorylation at the S396 site, activates Wnt signaling pathway.
-
CCG 203769
CCG 203769 is a selective inhibitor of RGS4 with an IC50 of 17 nM for the RGS4-Gαo protein-protein interaction.
